Evidence map›Paper›PMID 15674352›Full record

ArticleOncogene2005

Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling.

Viqar Syed, Kasturi Mukherjee, James Lyons-Weiler, Kin-Mang Lau, Tetsuo Mashima, Takashi Tsuruo, Shuk-mei Ho

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Targeting purine metabolism in ovarian cancer.Journal of ovarian research · 2022
    Review
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Different Role of Caveolin-1 Gene in the Progression of Gynecological Tumors.Asian Pacific journal of cancer prevention : APJCP · 2019
    Review
  13. Article
  14. ATF3 Repression of BCL-XClinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Viqar SyedDepartment of Surgery, University of Massachusetts Medical School, Worcester, MA 06105, USA.
Kasturi Mukherjee
James Lyons-Weiler
Kin-Mang Lau
Tetsuo Mashima
Takashi Tsuruo
Shuk-mei Ho

Funding

CYP1A1, estrogen metabolism and ovarian carcinogenesisR01CA094221 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 2002 to 2004
$935k
Molecular Mechanism of Neoplastic TransformationR03CA091250 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SYED, VIQAR · 2002 to 2003
$159k
NCI NIH HHS CA091250NCI NIH HHS CA94221
6 · The paper itself

Abstract

Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial (HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional profiling with a cDNA microarray containing approximately 2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and (2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 (NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes for OCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.

Indexed as

Activating Transcription Factor 3Caspase 3CaspasesCaveolin 3CaveolinsEnzyme ActivationFemaleGene Expression ProfilingGenes, Tumor SuppressorGTPase-Activating ProteinsHumansNM23 Nucleoside Diphosphate KinasesNucleoside-Diphosphate KinaseOvarian NeoplasmsProgesteroneRNA, MessengerActivating Transcription Factor 3CASP3 protein, humanCaspase 3CaspasesCAV3 protein, humanCaveolin 3CaveolinsDLC1 protein, humanGTPase-Activating ProteinsNM23 Nucleoside Diphosphate KinasesNME1 protein, humanNucleoside-Diphosphate KinaseProgesteroneRNA, MessengerTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID15674352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.